Professor Paul Timpson
Garvan Institute of Medical Research (NSW)
$450,000
2024 - 2027
The Research
Due to surgically unresectable, advanced disease being present at the time of diagnosis, pancreatic cancer is one of the most lethal forms of human cancer, with >90% of patient deaths occurring within 1 year of diagnosis. Systemic therapies are largely ineffective for inoperable disease. Recent work however at our Institute has shown that a number of patients harbour high levels of fibrosis, make them exquisitely sensitive to anti-fibrotic therapy. This may be enhanced by combination with gemcitabine/Abraxane and can only be seen when looking in live tissue.
Consequently, the development of more effective strategies to maximise this new opportunity in pancreatic cancer is urgently required.
share
.svg)
